Hosted on MSN19d
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
Jefferies analysts led by Roger Song see significant value in the company based on its leading GLP-1/GIP franchise, setting a $110 price target on shares, reflecting a 223% upside to the current ...